DUBLIN – It's the kind of deal that says a lot more about a company's scientific chops than about its financial prospects, but Erytech Pharma SA entered an agreement with SQZ Biotechnologies Inc., under which the latter firm will have exclusive access to Erytech's red blood cell (RBC) platform for therapies that modulate the immune system.